Which manufacturer savings or direct-pay options may apply to Ozempic?

Eligible, commercially insured patients can use the Ozempic® Savings Card, while uninsured patients may qualify for the Novo Nordisk Patient Assistance Program.

Ozempic Manufacturer Savings Card

Novo Nordisk, the manufacturer of Ozempic®, offers a savings card to help reduce out-of-pocket costs for eligible patients. This program is specifically designed for individuals with private or commercial health insurance.

With an activated card, eligible patients may pay as little as $25 for a 1-month, 2-month, or 3-month prescription. The program provides a maximum savings of $150 per 1-month supply, $300 per 2-month supply, and $450 per 3-month supply.

This offer is not valid for patients whose prescriptions are paid for by any state or federally funded programs, including Medicare or Medicaid. The program is subject to a calendar year maximum benefit, and other specific terms and conditions apply.

Novo Nordisk Patient Assistance Program (PAP)

For U.S. patients without insurance or with insufficient coverage, Novo Nordisk operates a Patient Assistance Program (PAP). This program is designed to provide medications, including Ozempic®, at no cost to those who qualify based on need.

Eligibility for the PAP is primarily based on household income, which must be at or below 400% of the federal poverty level. Applicants must also be U.S. citizens or legal residents and have no other prescription drug coverage through private insurance or government programs like Medicare Part D.

The application process requires submitting proof of income, household size, and a valid prescription from a licensed healthcare provider. If an applicant is approved, the medication is typically shipped directly to the patient's home or their clinician's office.

Insurance Coverage and Prior Authorization

Most insurance plans, including commercial policies and Medicare Part D, require prior authorization (PA) before covering Ozempic®. This is a standard process for high-cost, specialty medications to ensure appropriate use.

Insurers generally only approve coverage for Ozempic® for its primary FDA-approved indication: to improve glycemic control in adults with type 2 diabetes mellitus. Coverage for off-label use, such as chronic weight management alone, is commonly denied.

The prior authorization process requires your physician to submit clinical documentation to your insurance provider. This typically includes lab results showing an elevated A1c, a formal diagnosis of type 2 diabetes, and often a documented history of failure with first-line therapies like metformin.

Limitations for Government-Funded Insurance

Federal anti-kickback statutes legally prohibit patients with government-funded insurance from using manufacturer co-pay cards and other savings programs. This restriction applies to anyone with Medicare, Medicaid, TRICARE, or VA benefits.

These patients must rely on their plan's formulary for coverage. The final out-of-pocket cost depends on where Ozempic® is placed on the formulary's tiers and the patient's current stage of coverage, such as their annual deductible or the Part D coverage gap.

If Ozempic® is not on their plan's formulary or the cost remains prohibitive, the only manufacturer-sponsored option is the Patient Assistance Program (PAP), provided the patient meets the program's strict income and insurance-status requirements.

Direct-Pay and Telehealth Options

For patients without any insurance coverage, the U.S. list price for a one-month supply of Ozempic® typically exceeds $950. This retail 'cash price' can vary significantly between pharmacies, so comparing prices may yield some savings.

Direct-pay is a viable, though expensive, option for those who face insurance denials or have very high deductibles. Some patients use pharmacy discount cards (which are separate from manufacturer savings programs) to slightly reduce the cash price.

Physician-supervised telehealth practices like GOAL.MD can help patients navigate the complex landscape of medication access. This includes managing the prior authorization process and, as part of a comprehensive [weight-loss](/weight-loss) program, evaluating all appropriate medication options based on a patient's clinical profile and financial constraints.

Bottom Line

Available savings for Ozempic® are dictated by your insurance status. The manufacturer savings card is for commercially insured patients, while the Patient Assistance Program serves the uninsured who meet income criteria.

Insurance coverage is nearly always contingent on a successful prior authorization proving medical necessity for its FDA-approved use in type 2 diabetes.

Patients with government-funded insurance cannot use savings cards, and the direct-pay cash price for brand-name Ozempic® remains high for most individuals.

This information is for educational purposes only and does not constitute medical advice.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.